MING L ZHANG
Real Estate Commission in Philadelphia, PA
License number
Pennsylvania RS319252
Category
Real Estate Commission
Type
Real Estate Salesperson-Standard
Address
Address
Philadelphia, PA 19120
Personal information
See more information about MING L ZHANG at radaris.comName
Address
Phone
5325 Claridge St, Philadelphia, PA 19124
556 E Linden St, Fleetwood, PA 19522
8789 Duveen Dr, Glenside, PA 19038
Professional information
Postdoc At Temple University Health System
Position:
Postdoc at Temple University Health System
Location:
Greater Philadelphia Area
Industry:
Health, Wellness and Fitness
Work:
Temple University Health System
-
Postdoc
Dr. Ming Zhang, Philadelphia PA - MD (Doctor of Medicine)
Specialties:
Anatomic & Clinical Pathology
Address:
3401 N Broad St SUITE 2ND, Philadelphia 19140
(215) 707-3923 (Phone)
(215) 707-3923 (Phone)
Languages:
English
Hospitals:
3401 N Broad St SUITE 2ND, Philadelphia 19140
Temple University Hospital
3401 North Broad St, Philadelphia 19140
Temple University Hospital
3401 North Broad St, Philadelphia 19140
Partner At Orchid 3D
Position:
Partner at Orchid 3D
Location:
Greater Philadelphia Area
Industry:
Animation
Work:
Orchid 3D
-
Partner
Ming Zhang, Philadelphia PA
Work:
Panphil Realty
Philadelphia
(267) 269-7286
Philadelphia
(267) 269-7286
Inflammation Therapy
US Patent:
2008013, Jun 12, 2008
Filed:
Dec 5, 2007
Appl. No.:
11/950456
Inventors:
Billy R. Martin - Richmond VA, US
Mohamad Imad Damaj - Richmond VA, US
Martin W. Adler - Philadelphia PA, US
Ronald F. Tuma - Philadelphia PA, US
Ming Zhang - Philadelphia PA, US
Anu Mahadevan - Woburn MA, US
Raj K Razdan - Woburn MA, US
Mohamad Imad Damaj - Richmond VA, US
Martin W. Adler - Philadelphia PA, US
Ronald F. Tuma - Philadelphia PA, US
Ming Zhang - Philadelphia PA, US
Anu Mahadevan - Woburn MA, US
Raj K Razdan - Woburn MA, US
International Classification:
A61K 31/4164, A61P 25/28, A61K 31/045
US Classification:
514397, 514734
Abstract:
A method is provided for treating a patient in need of therapy for central nervous system inflammation comprising administering to that patient a therapeutically effective amount of a cannabinoid agonist having efficacy at the CBreceptor but having substantially no efficacy at the CBreceptor at that amount.